PIVOT IO 011: A Phase 1/2 Study of Bempegaldesleukin (BEMPEG; NKTR-214) Plus Nivolumab (NIVO) and Tyrosine Kinase Inhibitor (TKI) Versus NIVO and TKI Alone in Patients (pts) with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (Mrcc).
Journal of clinical oncology（2022）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined